SCHEMBL26175461

SCHEMBL26175461

c1cncc(-c2cnc3[nH]cc(-c4ccc5nccn5n4)c3c2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.58
CCNA2 P20248 1/20 0.58
CDK2 P24941 1/20 0.58
CDK9 P50750 1/20 0.58
PDPK1 O15530 2/20 0.56
DYRK1A Q13627 3/20 0.53
PIK3CA P42336 3/20 0.53
NTRK1 P04629 3/20 0.53
KIT P10721 1/20 0.52
PRKCI P41743 1/20 0.51
NEK1 Q96PY6 2/20 0.50
AXL P30530 3/20 0.49
CDK8 P49336 2/20 0.49
TNIK Q9UKE5 1/20 0.49
PLCG1 P19174 1/20 0.48
SGK1 O00141 1/20 0.44
CAMKK2 Q96RR4 1/20 0.44
CLK1 P49759 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26175256 0.91 AXL (0.60) PDPK1NTRK1PRKCIAXLCDK8
SCHEMBL26175497 0.83 PRKCI (0.47) CCNT1CCNA2CDK2CDK9PDPK1
SCHEMBL26175533 0.83 PRKCI (0.49) CCNT1CCNA2CDK2CDK9PDPK1
SCHEMBL26175297 0.82 KIT (0.52) CCNT1CCNA2CDK2CDK9PDPK1
SCHEMBL26174511 0.81 PRKCI (0.66) CCNT1CCNA2CDK2CDK9PDPK1
SCHEMBL26175345 0.81 PDPK1 (0.56) PDPK1
SCHEMBL26174709 0.80 PRKCI (0.54) CCNT1CCNA2CDK2CDK9DYRK1A
SCHEMBL26174746 0.80 PRKCI (0.54) CCNT1CCNA2CDK2CDK9PDPK1
SCHEMBL26174664 0.80 PRKCI (0.54) CCNT1CCNA2CDK2CDK9DYRK1A
SCHEMBL26175448 0.80 KIT (0.58) CCNT1CCNA2CDK2CDK9PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF TENARX, INC. 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192686-A1 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CCNT1 1256/4885CCNA2 1087/4885CDK2 212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.